AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27715335 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium (IND/GLY) 110/50 μg once daily
Number of subjects: 744
Study 27715335 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/Fluticasone (SFC) 50/500 μg twice daily
Number of subjects: 744
Study 27715335 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium (IND/GLY)
Number of subjects: 744
Study 27715335 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/Fluticasone (SFC)
Number of subjects: 744
Study 24255993 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐h ultrasonic debridement with frequent oral hygiene reinforcement (OHI) over four visits
Number of subjects: 44
Study 24255993 — intervention group
Group type: COMPARATOR
Intervention: 1‐h ultrasonic debridement without frequent oral hygiene reinforcement (control)
Number of subjects: 44
Study 23025477 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised QUOTE‐CNSLD instrument completed by parents at baseline (T0), after 1 year (T1), and after 2 years (T2)
Number of subjects: 107
Study 23025477 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-item 'child-specific' questionnaire about their caregiver, completed by children
Number of subjects: 107
Study 23025477 — intervention group
Group type: COMPARATOR
Intervention: Quality of care in different follow-up settings (general practitioner, pediatrician, specialized asthma nurse)
Number of subjects: 107
Study 23025477 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma-specific domain of the revised QUOTE‐CNSLD instrument
Number of subjects: 107
Study 23025477 — intervention group
Group type: COMPARATOR
Intervention: Quality aspects derived from scores in all three study groups
Number of subjects: 107
Study 19653573 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil plus oral scopolamine (MS)
Number of subjects: 60
Study 19653573 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil plus placebo (MP)
Number of subjects: 60
Study 19653573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (DP)
Number of subjects: 60
Study 17595750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine in combination with standard anti-anginal medications
Number of subjects: 0
Study 17595750 — intervention group
Group type: COMPARATOR
Intervention: Standard anti-anginal medications only
Number of subjects: 0
Study 17595750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine added to standard treatment
Number of subjects: 0
Study 17595750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 0
Study 15154368 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread made of bioactivated wheat grain
Number of subjects: 45
Study 12002509 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mm cobalt‐chromium head
Number of subjects: 89
Study 12002509 — intervention group
Group type: COMPARATOR
Intervention: 22 mm cobalt‐chromium head
Number of subjects: 89
Study 12002509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 10215735 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d., metronidazole 500 mg b.d., clarithromycin 500 mg b.d. for 1 week
Number of subjects: 50
Study 7474331 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 500 mg once daily for 3 days
Number of subjects: 90
Study 7474331 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM)
Number of subjects: 90
Study 2081275 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin 60 mg a day
Number of subjects: 22
Study 2081275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7426081 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen of nicotinic acid (up to 3 g daily) and 2 g of clofibrate daily
Number of subjects: 555
Study 7426081 — intervention group
Group type: COMPARATOR
Intervention: Control group on diet alone
Number of subjects: 555
Study 31810006 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility school attachment
Number of subjects: 569
Study 31810006 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility school experience
Number of subjects: 569
Study 31870345 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight Programme (HWP)
Number of subjects: 76
Study 31870345 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS intervention
Number of subjects: 76
Study 31870345 — intervention group
Group type: COMPARATOR
Intervention: GYM intervention
Number of subjects: 76
Study 28716236 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic treatment during hospitalization
Number of subjects: 3882
Study 28716236 — intervention group
Group type: COMPARATOR
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 3882
Study 28716236 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus (DM)
Number of subjects: 3882
Study 28716236 — intervention group
Group type: COMPARATOR
Intervention: Normal fasting plasma glucose
Number of subjects: 3882
Study 28716236 — intervention group
Group type: COMPARATOR
Intervention: No hypoglycemic treatment during hospitalization
Number of subjects: 3882
Study 25811948 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction with aerobic exercise (CR + EX)
Number of subjects: 70
Study 25811948 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction (CR)
Number of subjects: 70
Study 24955812 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS)
Number of subjects: 308
Study 24955812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 22770894 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow breathing
Number of subjects: 30
Study 22770894 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing
Number of subjects: 30
Study 22770894 — intervention group
Group type: COMPARATOR
Intervention: Fast breathing
Number of subjects: 30
Study 22770894 — intervention group
Group type: EXPERIMENTAL
Intervention: NFR (nociceptive flexion reflex)
Number of subjects: 30
Study 22770894 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV (heart rate variability)
Number of subjects: 30
Study 19019048 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 1:80,000
Number of subjects: 0
Study 19019048 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 1:160,000
Number of subjects: 0
Study 19019048 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine plain
Number of subjects: 0
Study 19019048 — intervention group
Group type: COMPARATOR
Intervention: Normal saline control
Number of subjects: 0
Study 19019048 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with epinephrine 1:320,000
Number of subjects: 0
Study 17564649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg/kg
Number of subjects: 60
Study 17564649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 4 µg/kg
Number of subjects: 60
Study 17564649 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmucosal dexmedetomidine 1 µg/kg
Number of subjects: 60
Study 15151094 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 119
Study 15151094 — intervention group
Group type: COMPARATOR
Intervention: Neodolpasse (75 mg diclofenac and 30 mg orphenadine)
Number of subjects: 119
Study 15151094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 11903527 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox A (500 MU)
Number of subjects: 8
Study 11903527 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 8
Study 9486756 — intervention group
Group type: EXPERIMENTAL
Intervention: New SSRIs (fluvoxamine, paroxetine, sertraline)
Number of subjects: 267
Study 9486756 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonteratogenic agents)
Number of subjects: 267
Study 7991322 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-determination factors (self-confidence, positive attitude, listening skills, assuming responsibility)
Number of subjects: 40
Study 7991322 — intervention group
Group type: COMPARATOR
Intervention: Role models
Number of subjects: 40
Study 2733675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanguinarine mouthrinses
Number of subjects: 0
Study 2733675 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwashes
Number of subjects: 0
Study 30558852 — intervention group
Group type: EXPERIMENTAL
Intervention: PRE-RA arm (n=78)
Number of subjects: 238
Study 30558852 — intervention group
Group type: EXPERIMENTAL
Intervention: PRE-RA Plus arm (n=80)
Number of subjects: 238
Study 30558852 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm (n=80)
Number of subjects: 238
Study 27376466 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐α inhibitors
Number of subjects: 0
Study 26380439 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Tongtu Granule (CTG), 14.3 g per package, twice daily for 14 days
Number of subjects: 80
Study 26380439 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 14.3 g per package, twice daily for 14 days
Number of subjects: 80
Study 23638621 — intervention group
Group type: EXPERIMENTAL
Intervention: Merional‐HG
Number of subjects: 157
Study 23638621 — intervention group
Group type: COMPARATOR
Intervention: Menopur
Number of subjects: 157
Study 22114973 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise regime 'Hip School' (n = 70)
Number of subjects: 217
Study 22114973 — intervention group
Group type: COMPARATOR
Intervention: Non‐intervention control group (n = 70)
Number of subjects: 217
Study 22114973 — intervention group
Group type: COMPARATOR
Intervention: 'Sham' ultrasound group (n = 70)
Number of subjects: 217
Study 22114973 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound group (n = 7)
Number of subjects: 217
Study 19170453 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback
Number of subjects: 295
Study 19170453 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 295
Study 16722029 — intervention group
Group type: EXPERIMENTAL
Intervention: New bicarbonate/lactate-buffered solution (N)
Number of subjects: 13
Study 16722029 — intervention group
Group type: COMPARATOR
Intervention: Gambrosol trio (GT)
Number of subjects: 13
Study 15193680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/day
Number of subjects: 506
Study 15193680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg/day
Number of subjects: 506
Study 15193680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 11768453 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance system and collaborative interventions involving state and federal agencies, industry, labor, and professional organizations.
Number of subjects: 0
Study 11768453 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative efforts to improve safety in helicopter lift operations.
Number of subjects: 0
Study 11768453 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of surveillance data for action.
Number of subjects: 0
Study 9247776 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg elemental iron (Polysaccharide complex, Central Pharmaceuticals), twice daily for 3 months
Number of subjects: 49
Study 9247776 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 3 months
Number of subjects: 49
Study 7664425 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 1-antagonist (prazosin)
Number of subjects: 23
Study 7664425 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 2-antagonist (yohimbine)
Number of subjects: 23
Study 7664425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both alpha 1 and alpha 2 antagonists
Number of subjects: 23
Study 7664425 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral hand)
Number of subjects: 23
Study 2655692 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 micrograms of cyclopenthiazide
Number of subjects: 53
Study 2655692 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of cyclopenthiazide
Number of subjects: 53
Study 2655692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 2655692 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of cyclopenthiazide
Number of subjects: 53
Study 359382 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate
Number of subjects: 0
Study 359382 — intervention group
Group type: COMPARATOR
Intervention: Meperidine hydrochloride
Number of subjects: 0
Study 31813657 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube (NGT) decompression
Number of subjects: 100
Study 31813657 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric tube (NGT) decompression
Number of subjects: 100
Study 30654713 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 29
Study 30654713 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 29
Study 27369737 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention starting at discharge and lasting three months, including exercises to increase range of motion and restore lung function and physical function.
Number of subjects: 64
Study 27369737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 64
Study 26682492 — intervention group
Group type: EXPERIMENTAL
Intervention: High accommodation by both parents
Number of subjects: 54
Study 26682492 — intervention group
Group type: EXPERIMENTAL
Intervention: High accommodation by one parent
Number of subjects: 54
Study 26682492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low accommodation by both parents
Number of subjects: 54
Study 26682492 — intervention group
Group type: EXPERIMENTAL
Intervention: High carer skills by both parents or mother alone
Number of subjects: 54
Study 26682492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carer skills by both parents
Number of subjects: 54
Study 23824662 — intervention group
Group type: EXPERIMENTAL
Intervention: sugammadex 4 mg/kg
Number of subjects: 132
Study 23824662 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 132
Study 23824662 — intervention group
Group type: EXPERIMENTAL
Intervention: neostigmine 50 μg/kg/glycopyrrolate 10 μg/kg
Number of subjects: 132
Study 21832216 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release pramipexole (0.375-4.5 mg/day)
Number of subjects: 507
Study 21832216 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release pramipexole (3 times daily)
Number of subjects: 507
Study 21832216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 19410086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo rotary instruments with manual glide path (using #08-15 K files)
Number of subjects: 40
Study 19410086 — intervention group
Group type: COMPARATOR
Intervention: Mtwo rotary instruments without manual glide path
Number of subjects: 40
Study 17078576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg administered 3 times/week (SCH)
Number of subjects: 418
Study 17078576 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 20 mg on demand (OD)
Number of subjects: 418
Study 17078576 — intervention group
Group type: COMPARATOR
Intervention: Preference for regimen
Number of subjects: 418
Study 15599840 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 26
Study 15599840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11728654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (multifaceted package including a workshop, written material, guidelines, and videos)
Number of subjects: 0
Study 11728654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 8908651 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin
Number of subjects: 140
Study 8908651 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 140
Study 8908651 — intervention group
Group type: COMPARATOR
Intervention: Estrogens
Number of subjects: 140
Study 1895958 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion (SRIF, 500 micrograms/h)
Number of subjects: 6
Study 1895958 — intervention group
Group type: EXPERIMENTAL
Intervention: SRIF infusion preceded by a nicotinic acid analogue (acipimox, 250 mg orally)
Number of subjects: 6
Study 1895958 — intervention group
Group type: EXPERIMENTAL
Intervention: SRIF plus insulin infusion
Number of subjects: 6
Study 1895958 — intervention group
Group type: EXPERIMENTAL
Intervention: SRIF plus insulin plus intralipid infusion
Number of subjects: 6
Study 1895958 — intervention group
Group type: EXPERIMENTAL
Intervention: SRIF plus insulin infusion plus acipimox
Number of subjects: 6
Study 1895958 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 6
Study 6628507 — intervention group
Group type: EXPERIMENTAL
Intervention: triamterene 10 mg i.v.
Number of subjects: 6
Study 6628507 — intervention group
Group type: COMPARATOR
Intervention: triamterene 50 mg p.o.
Number of subjects: 6
Study 30762320 — intervention group
Group type: EXPERIMENTAL
Intervention: Right nostril intubation
Number of subjects: 40
Study 30762320 — intervention group
Group type: COMPARATOR
Intervention: Left nostril intubation
Number of subjects: 40
Study 27309418 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mm deep grafts
Number of subjects: 33
Study 27309418 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mm deep grafts
Number of subjects: 33
Study 27309418 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mm superficial grafts
Number of subjects: 33
Study 27309418 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mm superficial grafts
Number of subjects: 33
Study 27309418 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep grafts
Number of subjects: 33
Study 27309418 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial grafts
Number of subjects: 33
Study 26069949 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza Vaccine (TIV)
Number of subjects: 231
Study 26069949 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 231
Study 25123343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 972
Study 25123343 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsample of cannabis users
Number of subjects: 972
Study 22919307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea‐flavor liquor (TFL)
Number of subjects: 45
Study 22919307 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese liquor (TCL)
Number of subjects: 45
Study 19940820 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) with 5 mL of 0.5% levobupivacaine at T9-L1 levels
Number of subjects: 60
Study 19940820 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (SA) with 8 mg of 0.5% hyperbaric levobupivacaine at L2-L3 level
Number of subjects: 60
Study 17633796 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (group A) at a mean dose of 37.5 mg once a day (n = 14)
Number of subjects: 28
Study 17633796 — intervention group
Group type: COMPARATOR
Intervention: No spironolactone (group B) (n = 14)
Number of subjects: 28
Study 15122957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone (DHEA; 100 mg/day)
Number of subjects: 23
Study 15122957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12366874 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal coherence measures of sleep EEG rhythms
Number of subjects: 47
Study 12366874 — intervention group
Group type: COMPARATOR
Intervention: Standard sleep measures
Number of subjects: 47
Study 9667268 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative chemotherapy with autologous bone marrow rescue (ABMR)
Number of subjects: 20
Study 9667268 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative chemotherapy with ABMR followed by external-beam irradiation
Number of subjects: 20
Study 7713852 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate switch to 20 mg of paroxetine daily after last dose of fluoxetine (N = 123)
Number of subjects: 242
Study 7713852 — intervention group
Group type: COMPARATOR
Intervention: Placebo-washout followed by 20 mg of paroxetine daily (N = 119)
Number of subjects: 242
Study 1693474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicumarol (coumarin derivative) orally postoperatively
Number of subjects: 116
Study 1693474 — intervention group
Group type: COMPARATOR
Intervention: Heparin (postoperative treatment for all patients)
Number of subjects: 116
Study 1693474 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical ischemia
Number of subjects: 116
Study 1693474 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoro‐distal reconstructions
Number of subjects: 116
Study 111467 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 34
Study 111467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30506981 — intervention group
Group type: EXPERIMENTAL
Intervention: EDAPTS plus TAU
Number of subjects: 96
Study 30506981 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 96
Study 27926575 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure dressing
Number of subjects: 50
Study 27926575 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 50
Study 25088921 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution white-light endoscopy (HR-WLE)
Number of subjects: 52
Study 25088921 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 52
Study 25088921 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HR-WLE and NBI
Number of subjects: 52
Study 24114718 — intervention group
Group type: EXPERIMENTAL
Intervention: Start For Life treatment (30 min per day)
Number of subjects: 306
Study 24114718 — intervention group
Group type: EXPERIMENTAL
Intervention: Start For Life treatment
Number of subjects: 306
Study 24114718 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition (30 min per day)
Number of subjects: 306
Study 21527516 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated double umbilical cord blood (dUCB) transplantation
Number of subjects: 100